Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hiroshi Mizuguchi
Observed name:
H. Mizuguchi
Institution:
Otsuka (Japan)
Observed institutions:
Otsuka (Japan),
The University of Osaka
OpenAlex ID:
A5026616338
Protective effect against Parkinson's disease-related insults through the activation of XBP1
2008
·
Megumi Sado
, Yuki Yamasaki
, et al.
·
Brain Research
·
170
Thermolabile phenotype of carnitine palmitoyltransferase II variations as a predisposing factor for influenza‐associated encephalopathy
2005
·
Y. Chen
, H. Mizuguchi
, et al.
·
FEBS Letters
·
97
PDF
Thermal instability of compound variants of carnitine palmitoyltransferase II and impaired mitochondrial fuel utilization in influenza-associated encephalopathy
2008
·
Dengbing Yao
, Hiroshi Mizuguchi
, et al.
·
Human Mutation
·
85
Tolvaptan Delays the Onset of End-Stage Renal Disease in a Polycystic Kidney Disease Model by Suppressing Increases in Kidney Volume and Renal Injury
2014
·
Miki Aihara
, Hiroyuki Fujiki
, et al.
·
Journal of Pharmacology and Experimental Therapeutics
·
72
Characterization and Application to Hot Start PCR of Neutralizing Monoclonal Antibodies against KOD DNA Polymerase
1999
·
H. Mizuguchi
, M. Nakatsuji
, et al.
·
The Journal of Biochemistry
·
63
Protective effects of XBP1 against oxygen and glucose deprivation/reoxygenation injury in rat primary hippocampal neurons
2012
·
Tatsuki Ibuki
, Yuki Yamasaki
, et al.
·
Neuroscience Letters
·
35
Enhanced Signal Transduction by a Directly Fused Protein of Interleukin-6 and Its Receptor.
2001
·
Hiroshi Mizuguchi
, Haruo Mizuno
, et al.
·
Journal of Bioscience and Bioengineering
·
9
In vitro and in vivo pharmacological profile of OPC-61815, a water-soluble phosphate ester pro-drug of tolvaptan
2022
·
Hiroyuki Fujiki
, Masayuki Matsunaga
, et al.
·
Journal of Pharmacological Sciences
·
7
PDF
Screening of an oligopeptide antagonist for interleukin-6 from a random phage library
2000
·
Hiroshi Mizuguchi
, Tomoko Kubomi
, et al.
·
Biotechnology Letters
·
5
Tolvaptan, a vasopressin V2 receptor antagonist, is the world’s first approved drug for treatment of autosomal dominant polycystic kidney disease (ADPKD)
2022
·
Yoshihisa Yamada
, Hiroyuki Fujiki
, et al.
·
Folia Pharmacologica Japonica
·
2
PDF
Tolvaptan, a vasopressin V2 receptor antagonist, is the world’s first approved drug for treatment of autosomal dominant polycystic kidney disease (ADPKD)
2021
·
Yoshihisa Yamada
, Hiroyuki Fujiki
, et al.
·
Proceedings for Annual Meeting of The Japanese Pharmacological Society
·
1
PDF
Show more works
View as search
Works count:
11
Citation count:
546
H-index:
7
I10-index:
6
Year
Topic
Type